Members of the FDA advisory committee voted 9 to 2 that human trials of MDMA did not prove its efficacy, and 10 to 1 that its risks outweigh benefits.
The FDA's limited ability to evaluate psychiatric treatments was underscored by the decision on MDMA, even though the drug's effects were perceived as strong by committee members.
[
Collection
]
[
|
...
]